UBS O'Connor’s GSK GSK Stock Holding History

UBS O'Connor’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-71,000	Closed	-$2.9M	–	493
2024 Q3	$2.9M	Buy	+71,000	New	+$2.9M	0.07%	134
2023 Q4	–	Sell	-209,552	Closed	-$7.6M	–	551
2023 Q3	$7.6M	Buy	209,552 +85,000	+68%	+$3.02M	0.14%	80
2023 Q2	$4.44M	Buy	124,552 +6,136	+5%	+$220K	0.09%	137
2023 Q1	$4.21M	Buy	+118,416	New	+$4.14M	0.1%	157
2022 Q4	–	Sell	-165,076	Closed	-$4.86M	–	137
2022 Q3	$4.86M	Buy	+165,076	New	+$6.26M	0.06%	223

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

UBS O'Connor's GSK Position: Q4 2024 in Review

UBS O'Connor sold out of GSK (GSK) in Q4 2024, closing a stake of 71,000 shares — an estimated $2.9M sold.

UBS O'Connor first reported a position in GSK in Q3 2022 and held it in 5 quarters. The position peaked at $7.6M in Q3 2023. 848 funds tracked by Wall St. Rank hold GSK as of Q4 2024.

UBS O'Connor reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
UBS O'Connor sold 71,000 GSK shares in Q4 2024, an estimated $2.9M.
UBS O'Connor first reported a position in GSK in Q3 2022 and held it in 5 quarters.
UBS O'Connor's GSK position peaked at $7.6M in Q3 2023.
848 funds tracked by Wall St. Rank held GSK as of Q4 2024.

Based on UBS O'Connor's 13F filing for Q4 2024, filed 14 Feb 2025.